-

RIVN STOCK INVESTIGATION: Robbins LLP Reminds Investors That It Is Investigating Rivian Automotive, Inc. (RIVN) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP is investigating Rivian Automotive, Inc. (NASDAQ: RIVN) and its officers and directors to determine if the Company made false and misleading statements in its Offering Documents in Support of its initial public offering ("IPO").

If you would like more information about our investigation into Rivian Automotive, Inc.'s misconduct, click here.

What this Investigation is About: Rivian designs and manufactures electric vehicles – the R1T electric pickup truck and R1S electric SUV. Rivian began selling the R1T in September 2021 and planned to begin selling the R1S in December 2021. As of October 31, 2021, Rivian reported "approximately 55,400 R1T and R1S preorders in the United States and Canada from customers who paid a cancellable and fully refundable deposit of $1,000." At the time of its IPO, Rivian planned to produce approximately 1,200 R1Ts and 25 R1Ss by the end of 2021, with all preorders filled by the end of 2023.

Rivian completed its IPO on November 10, 2021, selling shares at $78.00 per share for total proceeds of $11.93 billion. However, unbeknownst to investors, the Registration Statement failed to disclose that Rivian underpriced the R1T and R1S to such a degree that the Company would have to raise prices shortly after the IPO. Subsequently, these price increases would tarnish Rivian's reputation as a trustworthy and transparent Company and would put a significant number of its backlog orders as well as future orders in jeopardy of cancellation. Accordingly, the price of the Company's shares was artificially inflated at the time of the IPO. As Rivian announced its plans to increase its prices, its shares took a hit. Rivian stock now trades near $38.00 per share, significantly below the Company's $78.00 IPO price.

Next Steps: If you acquired shares of Rivian Automotive, Inc. pursuant to the Company's IPO, you have legal options. Contact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Rivian Automotive, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:RIVN

Release Summary
RIVN STOCK INVESTIGATION: Robbins LLP Reminds Investors that it is Investigating Rivian Automotive, Inc. (RIVN) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom